Um sarcoma que surge do osso. Exemplos representativos são o osteossarcoma e o condrossarcoma.
Introdução
O que você precisa saber de cara
Um sarcoma que surge do osso. Exemplos representativos são o osteossarcoma e o condrossarcoma.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 10 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 21 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
3 genes identificados com associação a esta condição.
Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T] (PubMed:37943659). Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, in
NucleusNucleus, PML bodyNucleus, nucleoplasm
Tumor predisposition syndrome 4
A disorder characterized by an increased risk for developing various types of benign and/or malignant neoplasms that arise at an accelerated rate and in different organs.
Tumor suppressor that is a key regulator of the G1/S transition of the cell cycle (PubMed:10499802). The hypophosphorylated form binds transcription regulators of the E2F family, preventing transcription of E2F-responsive genes (PubMed:10499802). Both physically blocks E2Fs transactivating domain and recruits chromatin-modifying enzymes that actively repress transcription (PubMed:10499802). Cyclin and CDK-dependent phosphorylation of RB1 induces its dissociation from E2Fs, thereby activating tra
NucleusCytoplasm
Childhood cancer retinoblastoma
Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.
Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop
CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome
Medicamentos e terapias
Mecanismo: Nucleotide-binding oligomerization domain-containing protein 2 other
Mecanismo: DNA topoisomerase II alpha inhibitor
Mecanismo: Tubulin inhibitor
Mecanismo: DNA topoisomerase II alpha inhibitor
Mecanismo: Tubulin inhibitor
Mecanismo: DNA topoisomerase II inhibitor
Mecanismo: Serine/threonine-protein kinase mTOR inhibitor
Variantes genéticas (ClinVar)
7,017 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
50 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Sarcoma ósseo
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
679 ensaios clínicos encontrados, 6 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 922
Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy.
Chondrosarcomas (ChSs) are mesenchymal chemo- and radiation-resistant tumors, representing the second most frequently diagnosed bone sarcoma after osteosarcoma and 20% of all bone sarcomas. Most of ChS patients have a good prognosis after complete surgical resection. Conversely, patients with inoperable disease, due to the tumor location or metastatic dissemination, represent a great clinical challenge due to the lack of effective therapeutic options. In this study, to the best of our knowledge, we document, for the first time in human ChS tissues, the existence of CD-31- and Podoplanin-negative vascular-like channels containing red blood cells, allowing us to hypothesize the occurrence of vasculogenic mimicry (VM) in ChSs. By using patient-derived ChS cells and a stabilized ChS cell line, we demonstrate that ChS cells are able to form in vitro tubules apparently similar to those formed by endothelial cells. Further characterization of these vessels revealed the pivotal role of the Urokinase Plasminogen Activator Receptor (uPAR) in mediating the capability of ChS cells to form VM. Finally, we provide evidence that, unlike bevacizumab, which did not exert any effect, the uPAR-derived antiangiogenic peptide RI-3 behaves as a potent inhibitor of VM.
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.
Chondrosarcoma (ChS) is a rare bone malignancy with heterogeneous behavior, the molecular and immunological background of which remains unknown. No effective systemic treatment for advanced ChS patients is available. The aim of this study was to develop an immune-mutational classification of ChS and to search for novel prognostic factors and molecular targets. We performed an immunological-molecular profiling of 99 patients diagnosed with primary ChS G1-G3 and dedifferentiated ChS. An expression of 20 immune response markers was assessed by IHC and targeted the next-generation sequencing of 409 genes was performed. Immunological and mutational profiles were correlated with overall survival using a multivariate LASSO-penalized Cox model. Three immunophenotypes were described-"cold" (IMP1), "hot" (IMP2), and "intermediate" (IMP3). IMP1 was the most prevalent in G1 cases, while IMP2 was the most prevalent in dedifferentiated cases. IDH1/2 or TP53 mutations were associated with high-grade ChS (FDR < 0.05). IMP2 was characterized by a higher number of immune infiltrates in the central region of the tumor (HR: 3.3; CI: 1.13-9.8; p < 0.05). IDH1 mutations were present most often in IMP2 cases (HR: 3.8; CI: 1.75-8.1; p < 0.001). Tumor size, dedifferentiated subtype, IDH1 mutation and the presence of IMP2 were identified as independent negative prognostic survival factors in ChS. An immune-mutational classification system for ChS patients was proposed, which may be used to identify those potentially suited for immunotherapy combined with IDH-mutant inhibitors in future research.
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Combination therapy with vibostolimab plus pembrolizumab has previously shown promising antitumor activity in melanoma. We aimed to evaluate the efficacy and safety of vibostolimab coformulated with pembrolizumab as adjuvant therapy for high-risk resected melanoma. This randomised, double-blind, phase 3 study was done at 205 global sites (hospitals and cancer centres). Participants aged 12 years or older with surgically resected, stage IIB-IV cutaneous melanoma per the American Joint Committee on Cancer Cancer Staging Manual 2017 (8th edition), with no evidence of metastatic disease after resection, were randomly assigned (1:1) to receive vibostolimab 200 mg coformulated with pembrolizumab 200 mg or pembrolizumab 200 mg alone intravenously every 3 weeks. Randomisation was done using an interactive response technology system and was stratified by risk-based staging and geographical region. Participants, investigators, and site staff were masked to group assignment. The primary endpoint was recurrence-free survival assessed in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of the study treatment. The protocol-prespecified first interim analysis was an event-driven nonbinding futility analysis of recurrence-free survival that was planned for when 111 events had occurred (futility bar of observed HR 0·95). This study is registered with ClinicalTrials.gov (NCT05665595), and is closed to recruitment. Between Jan 19, 2023, and March 6, 2024, 1402 participants were randomly assigned to receive coformulated vibostolimab-pembrolizumab (n=701) or pembrolizumab (n=701). At the first interim analysis, median study follow-up, defined as time from randomisation to data cutoff, was 4·2 months (IQR 1·9-6·7). The median age was 61·0 years (IQR 51·0-70·0), 829 (59%) of 1402 participants were male and 573 (41%) were female. 1107 (79%) of participants were White, 273 (19%) were Asian, and 22 (2%) were of other race or race was missing. At the time of the first interim analysis, a total of 119 (8%) of 1402 participants had had a recurrence-free survival event, including 67 (10%) of 701 in the vibostolimab-pembrolizumab group and 52 (7%) of 701 in the pembrolizumab alone group. The median recurrence-free survival was not reached in either group; the hazard ratio for recurrence-free survival in the vibostolimab-pembrolizumab group versus pembrolizumab alone group was 1·25 (95% CI 0·9-1·8). The most common (occurred in more than five participants) grade 3 or higher treatment-related adverse events were adrenal insufficiency in 13 (2%) participants, hepatitis in 11 (2%) participants, rash in 9 (1%) participants, maculopapular rash in 7 (1%) participants, and pruritus in 6 (1%) participants in the vibostolimab-pembrolizumab group and increased alanine aminotransferase in 7 (1%) participants in the pembrolizumab alone group. Treatment-related serious adverse events occurred in 74 (11%) participants and 30 (4%) participants, respectively. Treatment-related adverse events led to death in two (<1%) participants in the vibostolimab-pembrolizumab group (myasthenia gravis and myocarditis) and one participant (<1%) in the pembrolizumab group (myositis). The external data monitoring committee decided to discontinue the study according to prespecified futility criteria. Vibostolimab coformulated with pembrolizumab did not provide additional clinical benefit versus pembrolizumab as adjuvant therapy in participants with resected stage IIB-IV melanoma. Pembrolizumab monotherapy remains a standard of care for resected high-risk melanoma. Merck Sharp & Dohme, a subsidiary of Merck & Co.
Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.
Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal mesenchymal tumor, driven by tyrosine-protein kinase KIT and platelet-derived growth factor receptor A (PDGFRA) mutations. Specific variants, such as KIT exon 11 deletions, carry prognostic and therapeutic implications, whereas wild-type (WT) variants derive limited benefit from tyrosine kinase inhibitors (TKIs). Given the limited reproducibility of established clinicopathological risk models, deep learning (DL) applied to whole-slide images (WSIs) emerged as a promising tool for molecular classification and prognostic assessment. We analyzed 8398 GIST cases from 21 centers in 7 countries, including 7238 with molecular data and 2638 with clinical follow-up. DL models were trained on WSIs to predict mutations, treatment sensitivity, and recurrence-free survival (RFS). DL predicted mutational status in GIST from WSIs, with area under the curve (AUC) of 0.87 for KIT, 0.96 for PDGFRA. High performance was observed for subtypes, including KIT exon 11 del-inss 557-558 (0.67) and PDGFRA exon 18 D842V (0.93). For therapeutic categories, performance reached 0.84 for avapritinib sensitivity, 0.81 for imatinib sensitivity. DL models predicted RFS, with hazard-ratios (HR) of 8.44 (95%CI 6.14-11.61) in the overall cohort and 4.74 (95%CI 3.34-6.74) in patients receiving adjuvant therapy. Prognostic performance was comparable to pathology-based scores, with highest discrimination in the overall cohort and in patients without adjuvant therapy (9.44, 95%CI (5.87-15.20)). DL applied to WSIs enables prediction of molecular alterations, treatment sensitivity, and RFS in GIST, performing comparably to established risk scores across international cohorts, providing a baseline for future multimodal predictors.
Recycled tumor bone and/or vascularised fibula graft reconstruction for intercalary resections for sarcoma of femur.
Sarcomas of bone requiring an intercalary resection of femur are rare and challenging. In the absence of set guidelines, they are variously managed with intercalary prosthesis, cement spacers, allografts, recycled tumor bone, and autografts. We have used recycled tumor bone and/or vascularised fibula over the years for such resections. In this first-of-its-kind study on Indian patients, we aim to analyse the outcome of these procedures in femur. Twenty six patients undergoing an intercalary resection of femur from 2011 to 2024 by a single surgeon were analysed, of which one was excluded. All the patients underwent intercalary resection and reconstruction using recycled tumor and/or vascularised fibula. The demographic and surgical details, time to union, functional outcome and complications were analysed. 21 patients were treated with reimplantation of recycled tumor bone (extracorporeal radiation therapy (ECRT) in 15 and cryotherapy in 6). A vascularised fibula graft was used in 17 patients; as a stand-alone graft in 4 and in combination with recycled tumor bone in 13. After a mean follow up of 61.3 months (3-144 months), all patients showed union. Addition of a vascularised fibula graft to recycled tumor bone reduced the time to union (p = 0.02) without increasing the risk of a complication. Additionally, patients undergoing cryotherapy had shorter time to union (6.83 months) when compared to those who underwent ECRT (14.43 months), with fewer complications. (P = 0.02). Use of a vascularised fibula as a stand-alone graft took the maximum time to union. Resection length did not correlate with complication rates and functional outcome. Biological reconstruction after an intercalary resection of femur gives excellent long term results, with acceptable complication rates. We recommend the addition of a vascularised fibula graft to recycled tumor bone for intercalary resections of femur. Pedicled cryotherapy for recycling of tumor bone, when feasible, leads to fastest rehabilitation to optimal function.
Publicações recentes
Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?
Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease.
Physical activity after local therapy for pediatric bone sarcoma: an accelerometry-based analysis.
What shapes satisfaction with daily life participation? Insights into functional outcomes after pediatric bone sarcoma treatment.
The Role of Race and Ethnicity on Time to Treatment in Orthopaedic Oncology.
📚 EuropePMC531 artigos no totalmostrando 194
Computed Tomography Features of Pulmonary Metastatic Nodules Help Narrow the Differential Diagnosis of the Primary Tumor.
Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology AssociationVasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy.
CellsA press-fit tibial smooth stem may preserve proximal tibial physeal growth after expandable prosthesis reconstruction following resection of distal femur in children with bone sarcoma.
European journal of orthopaedic surgery & traumatology : orthopedie traumatologieGraft survival and prognostic factors of recycled autografts after limb salvage surgery in patients with sarcoma of the long bone: a systematic review and meta-analysis of individual participant data.
Journal of orthopaedic surgery and researchNeoadjuvant radiotherapy for primary retroperitoneal well-differentiated liposarcoma: a Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) propensity score matched analysis.
EClinicalMedicineDoes This Imaging Make Me Look NFATC2? The Value of Radiologic-pathologic Correlation in NFATC2-rearranged Sarcomas of Bone.
The American journal of surgical pathologyCase Report: Complete response to the concurrent neoadjuvant radiation therapy and pembrolizumab in a locally recurrent, chemotherapy-refractory undifferentiated pleomorphic sarcoma of bone.
Frontiers in oncologyCORR Insights®: Preliminary Surgical Findings and Complications After National Centralization of Pediatric Bone Sarcoma Resections in the Netherlands: a Benchmarking Study.
Clinical orthopaedics and related researchIntegrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.
International journal of molecular sciencesCalcineurin Homologous Protein 2 Acts as a Conditional Modulator of Migration and Proliferation in Human Bone Sarcoma Cells.
Cancers[Particle radiotherapy for sarcomas : Advantages, challenges and future perspectives].
Radiologie (Heidelberg, Germany)Molecular epidemiology of the expression of urokinase plasminogen activator receptor-associated protein (uPARAP) in mesenchymal malignancies.
Translational oncologyAn updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC).
European journal of cancer (Oxford, England : 1990)Utilizing bulk and single-cell RNA sequencing to identify potential biomarkers linked to angiogenesis and integrated stress response in chondrosarcoma.
Scientific reportsCounting matters: evidence from baseline CT prognostic parameters in pulmonary metastatic soft tissue and bone sarcoma.
European radiologyPrecision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.
International journal of nanomedicineESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.
Annals of oncology : official journal of the European Society for Medical OncologyVibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
The Lancet. OncologyReal-World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort.
Cancer medicineCurrent Treatment Standards for Metastatic Uveal Melanoma.
CancersA Systematic Review of Cutaneous Involvement in Metastatic Bone Sarcomas: Insights from 102 Reported Cases.
CancersIntroduction to animal modelling: factors and tools for choosing the optimal model for sarcoma research-a comprehensive literature review.
Translational cancer researchPrediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.
medRxiv : the preprint server for health sciencesEvaluation of Germline Pathogenic Variant of TP53 Gene in an Iranian Pedigree with Familial Sarcoma: A Case Report.
Advanced biomedical researchActivity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.
ESMO openLong-term Outcomes of 3-dimensional-printed Cutting Guides for Long Bone Sarcoma Resection and Intercalary Allograft Reconstruction: An Updated Case Series.
OrthopedicsDevelopment of a Health-Related Quality of Life Tool for Adolescents and Young Adults With Cancer.
JAMA network openAn In Vitro Investigation of 5-Aminolevulinic Acid Mediated Photodynamic Therapy in Bone Sarcoma.
Oncology researchAn analysis of palliative care in adolescents and young adults with soft tissue and bone sarcomas.
Palliative care and social practiceThe functional recovery trajectory in patients undergoing lower limb salvage surgery for bone tumour: an observational study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerCORR Insights®: Periacetabular Resection for Bone Tumors: Is There Still a Role for Massive Allograft-prosthesis Composite Reconstructions?
Clinical orthopaedics and related researchLAG-3 in (auto)immunity and cancer - Emphasising its role in antigen presenting cells.
Autoimmunity reviewsRecycled tumor bone and/or vascularised fibula graft reconstruction for intercalary resections for sarcoma of femur.
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association[Systemic treatment of bone sarcoma, soft tissue sarcoma, GIST].
La Revue du praticien[Surgical management of bone sarcomas].
La Revue du praticienStereotactic Body Radiotherapy vs. Metastasectomy for Soft Tissue and Bone Sarcoma Lung Metastases - A Systematic Review analyzing Safety and Efficacy.
Clinical and translational radiation oncologyImage-guided percutaneous interventions for bone tumors around the knee.
Skeletal radiology<p>Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review)</p>.
Oncology reportsHow Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic SurgeryChoosing the right animal model for sarcoma research.
Cellular and molecular life sciences : CMLSA Systematic Review and Meta-Analysis of Regorafenib's Effectiveness and Safety in the Treatment of Bone Sarcoma.
The archives of bone and joint surgeryLong-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis.
Journal of cancer research and clinical oncologyTime to treatment initiation and overall survival in osteosarcoma: a national cancer database analysis.
Bone & joint openCorrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].
ESMO openBaseline CT imaging parameters predicting overall and progression-free survival for patients with pulmonary metastases from soft tissue and bone sarcoma.
European radiologyExperience of periprosthetic infection in sarcoma patients following megaprosthetic reconstruction.
Bone & joint openRole of Repeat Core Needle Biopsy After Nondiagnostic Initial Biopsy for Soft Tissue and Bone Sarcoma: Systematic Review and Meta-Analysis.
Journal of surgical oncologyOutcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective study.
JTCVS openPathological fractures as an adverse prognostic factor in chondrosarcoma: Results of a systematic review, meta-analysis and institutional case series.
Journal of bone oncologyCurrent Strategies for Limb Salvage and Reconstruction in Pediatric Lower Extremity Malignant Bone Tumors: Focus on Growth Preservation and Functional Outcomes.
Children (Basel, Switzerland)Reirradiation for locally recurrent soft tissue sarcomas: A systematic review.
Clinical and translational radiation oncology3D-Printed Cut Guides and Custom Prostheses for Pelvic Reconstruction in Bone Sarcoma Patients: Complications, Survival Rates, and Functional Outcomes.
Orthopaedic surgeryClinicopathological and genomic profiling in undifferentiated pleomorphic sarcoma: Small series, clear message.
Journal of applied geneticsPreliminary Surgical Findings and Complications After National Centralization of Pediatric Bone Sarcoma Resections in the Netherlands: A Benchmarking Study.
Clinical orthopaedics and related researchEfficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis.
Frontiers in oncologyThe role of hyperthermia in modern radiation treatment- state of art.
Radiation oncology (London, England)Magnetic resonance imaging features of primary appendicular bone sarcomas in 20 dogs.
The Journal of small animal practiceManagement of pediatric bone sarcomas.
Current opinion in pediatricsCan endothelial cell dysfunction decide surgical wound health in bone sarcoma? Prospective study evaluating factors predicting wound complications in sarcoma.
Journal of clinical orthopaedics and traumaFunctional and oncological outcomes of distal femoral reconstruction in young children: A systematic review and meta-analysis.
Journal of children's orthopaedicsIdentification of a novel PRUNE2::NTRK2 gene fusion in soft tissue sarcoma patients-friend or foe? Case series.
Therapeutic advances in medical oncologyHypofractionated radiotherapy with hyperthermia in radiation-associated and in-volume recurrent soft tissue sarcomas of the extremities and trunk wall: results of a proof-of-concept prospective trial.
Radiation oncology (London, England)Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma.
Current oncology (Toronto, Ont.)Metastatic Bone Disease With Pathologic or Impending Pathologic Fractures: Resolve, Refer, or Collaborate.
Instructional course lecturesA multidisciplinary approach to assessing the impact of local therapy in pediatric bone sarcoma patients and survivors: a cross-sectional study of adverse events and health-related quality of life.
EClinicalMedicineInnovation by Female Surgeons in the 1880s-Charlotte Blake Brown, MD.
The American surgeonHistone deacetylase in human sarcomas.
The International journal of biological markersAn analysis of the distribution of bone and soft tissue sarcoma diagnoses and their disparities in Southwest Germany: a multicenter approach.
Frontiers in oncologyHistopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial.
JAMA network openMicroRNA bioinformatics in precision oncology: an integrated pipeline from NGS to AI-based target discovery.
Journal of applied genetics[Internal hemipelvectomy: periacetabular resection with hip transposition].
Operative Orthopadie und TraumatologiePredictive Value of Baseline Left Ventricular Global Longitudinal Strain for Cardiac Dysfunction in Patients with Moderate to High Risk of Cancer Therapy-Related Cardiovascular Toxicity.
Pharmaceuticals (Basel, Switzerland)Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study.
Translational lung cancer researchGenetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review.
Current oncology reportsSecond-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives.
Current treatment options in oncologyGuidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
JAMA oncologyHow does surgeon's experience impacts revision rates after nononcologic lower extremity total joint arthroplasty with a megaprosthesis?
Orthopaedics & traumatology, surgery & research : OTSRFrom pathogenesis to the patient's bedside: a comprehensive review of extraskeletal myxoid chondrosarcoma.
Journal of cancer research and clinical oncologyDermatofibrosarcoma Protuberans (DFSP): Current Treatments and Clinical Trials.
Current treatment options in oncology[New reconstructive technique for massive zone 2+1 pelvic defects after oncological resection].
Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)Dermatofibrosarcoma Protuberans (DFSP): Diagnostics and Molecular Pathology.
Current treatment options in oncologyTriangulating Timing, Tropism and Burden of Sarcoma Metastases: Toward Precision Surveillance and Therapy in a Real-World-Time Cohort.
CancersAn Integrated Clinical Genomic and Transcriptomic Subgrouping of Central Chondrosarcoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncTime to treatment initiation in primary extremity sarcomas: Determinants and oncological outcomes in a tertiary LMIC cancer center.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyRecurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium.
JCO precision oncologyExploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe.
ESMO openImproving oncological outcomes for pelvic bone sarcomas: Is it possible?
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyCoronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.
Pharmaceuticals (Basel, Switzerland)Efficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma.
Clinical and translational radiation oncologyPhase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).
Journal for immunotherapy of cancerHow to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.
Cancer treatment reviewsSynergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.
British journal of haematologyInsights Into Non-Classic Primary Bone Sarcomas in Children, Adolescents, and Young Adults: A French Descriptive Study.
Pediatric blood & cancerOrthopaedic Progress and Specialisation in the aG-DRG System: An Analysis from the Perspective of a Centre of the National Centre for Tumour Diseases with a Focus on Bone Sarcoma.
Zeitschrift fur Orthopadie und UnfallchirurgieBUB1 an Overexpressed Kinase in Sarcoma: Finding New Target Therapy for Osteosarcoma, Liposarcoma, Synovial Sarcoma, and Leiomyosarcoma.
BiomoleculesPlatelets in Hepatocellular Carcinoma-From Pathogenesis to Targeted Therapy.
CancersSupporting Participant Engagement in Cancer Genomics Research in Rare Cancers: A Qualitative Study of Patients, Caregivers, and Advocates.
Cancer control : journal of the Moffitt Cancer CenterGenetic Analysis of Osteosarcoma Cells in a 9-year-old Boy: Genes Involved in Cell Cycle Control.
Acta medica academicaHow to treat systemic recurrences following adjuvant immunotherapy.
Translational cancer researchReal-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres.
European journal of cancer (Oxford, England : 1990)Advances in liquid biopsy for bone and soft-tissue sarcomas.
International journal of clinical oncologyGeneration of patient-derived sarcoma organoids for personalized drug screening and precision cancer immunotherapy.
BiomaterialsComparative accuracy of core-needle and open biopsy in diagnosis, subtyping, and grading of head and neck bone and soft tissue sarcomas.
The British journal of oral & maxillofacial surgeryDNA Methylation Profiling Separates SDH-Deficient GISTs From KIT-PDGFRA-Driven GISTs and Identifies Predictive Biomarkers for Targeted Therapy.
The American journal of surgical pathologyDroplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer ResearchChemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors.
Contemporary oncology (Poznan, Poland)Hormonal treatment of aggressive angiomyxoma.
Current problems in cancerTherapeutic challenge of advanced melanoma: exceptional response to combined immunotherapy.
Polish archives of internal medicineUnraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047.
Clinical cancer research : an official journal of the American Association for Cancer ResearchCORR Insights®: Is Rotationplasty Still a Reasonable Reconstruction Option for Patients With a Femoral Bone Sarcoma? A Comparative Study of Patients With a Minimum of 20 Years of Follow-up After Rotationplasty and Lower Extremity Amputation.
Clinical orthopaedics and related researchDoes Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?
Clinical orthopaedics and related researchDiscontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD.
Targeted oncologyThromboprophylaxis in medical patients: a 2025 update of Polish recommendations.
Polish archives of internal medicineBody image of patients in follow-up for pediatric bone sarcoma: implications of tumor location and local therapy.
Journal of cancer survivorship : research and practiceDefining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study.
EClinicalMedicineDiagnostic work-up of lipomatous tumors: a decision-making analysis among European sarcoma centers.
Insights into imagingAvelumab plus axitinib in patients with advanced gastrointestinal stromal tumor.
European journal of cancer (Oxford, England : 1990)Incidence, risk factors, and prognostic impact of regional lymph node metastasis in bone sarcoma: a population-based cohort study.
Japanese journal of clinical oncologyThe prognostic value of the modified Glasgow Prognostic Score in the management of patients with chondrosarcoma : a multicentre study.
The bone & joint journalPre-clinical Murine Models of Bone Sarcomas.
Methods in molecular biology (Clifton, N.J.)Analysis of mRNA, miRNA, and DNA in Bone Cells by RT-qPCR and In Situ Hybridization.
Methods in molecular biology (Clifton, N.J.)Isolation and Characterization of Circulating Tumor Cells.
Methods in molecular biology (Clifton, N.J.)Targeting metastasis in paediatric bone sarcomas.
Molecular cancerLimb salvage and complication management after (sub-) total humerus resection for primary malignant bone tumors in early childhood.
Journal of orthopaedic surgery and researchRadiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration.
Annals of surgical oncologySkip Lesions in Chondrosarcoma: Is Whole Bone Imaging Necessary?
Journal of surgical oncologyInterleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha.
International journal of molecular sciencesLandscape of ultra-rare sarcomas: a nationwide study for epidemiology and prognosis.
ESMO openEstimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe.
European journal of cancer (Oxford, England : 1990)Quantity of lower muscle as a promising prognostic factor for overall survival in patients with bone and soft tissue sarcoma.
Surgical oncologyA multidisciplinary and structured approach for comprehensive evaluation of functional outcomes, adverse events, psychosocial outcomes and health-related quality of life after local therapy for bone sarcoma in children: protocol for a cross-sectional study.
Frontiers in pediatricsGenetic predisposition in sarcomas: clinical implications and management.
EClinicalMedicineIs Rotationplasty Still a Reasonable Reconstruction Option for Patients With a Femoral Bone Sarcoma? A Comparative Study of Patients With a Minimum of 20 Years of Follow-up After Rotationplasty and Lower Extremity Amputation.
Clinical orthopaedics and related researchA pattern of local failure after preoperative 5 × 5 Gy in soft tissue sarcomas: A long-term real-world experience.
Clinical and translational radiation oncologyPulmonary Metastasectomy in Sarcoma.
Thoracic surgery clinicsApplication of 3D printing for personalized boluses in radiotherapy: a systematic review.
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology[Recurrent or refractory Osteosarcoma and Ewing sarcoma-French guidelines from the FSG/NETSARC and GroupOs groups].
Bulletin du cancerPost-treatment late and long-term effects in bone sarcoma: A scoping review.
Journal of bone oncologyPrognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.
EClinicalMedicineThe reproductive system and breast metastases - a narrative review and case series of metastases from soft tissue and bone sarcomas in girls.
Polish journal of radiologyVascularized Free Fibula Flap for Limb Salvage After Long Bone Tumor Resection in Pediatric Patients: A Single-Center Seven-Year Experience From a Developing Country.
CureusConference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects.
European journal of cancer (Oxford, England : 1990)Establishment and characterization of NCC-OS2-C1: a novel patient-derived cell line of osteosarcoma.
Human cellMethylation Analysis Reveals Epigenetic Congruence Between Bone Sarcomas With H3-3A Mutations and Malignant Giant Cell Tumors of Bone.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncPrediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS Cohort.
JCO precision oncologyNeoadjuvant or Adjuvant Chemotherapy in Soft-Tissue Sarcoma?
Current oncology reportsDelay in Diagnosis and Treatment of Bone Sarcoma-Systematic Review.
CancersKnee-Sparing Resection and Reconstruction Surgery for Bone Sarcoma Using 3D-Surgical Approach: Average of 5-Year Follow-Up.
Medicina (Kaunas, Lithuania)Calvarial Chondroplastic Osteosarcoma With Distant Brain Metastasis Treated With Radiosurgery: A Rare Case Report.
Case reports in medicineDevelopment of a surgical complexity score to predict postoperative morbidity following primary retroperitoneal sarcoma resection: a collaborative study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
The British journal of surgeryImmune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.
European journal of cancer (Oxford, England : 1990)Subtype-Specific Patterns of Tumor Purity and Mutation Load Suggest Treatment Implications: A Cross-Sectional Analysis of 7494 Soft Tissue and Bone Sarcomas (MSK Cohort).
American journal of clinical oncologyLong-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study.
Cancer control : journal of the Moffitt Cancer CenterAmputation Versus Limb-Salvage Surgery as Treatments for Pediatric Bone Sarcoma: A Comparative Study of Survival, Function, and Quality of Life.
CureusRedefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
ESMO openSelinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice.
Medical oncology (Northwood, London, England)Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases.
BMJ oncologyLong-term Outcomes of Biological Reconstruction for Primary Bone Sarcoma of the Humerus.
Cancer diagnosis & prognosisCase Report: Bicondylar conjoined Hoffa fracture with incarcerated patella.
Frontiers in surgeryAn evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.
Expert review of anticancer therapyA Proof-of-Concept Solution for Co-locating 2D Histology Images in 3D for Histology-to-CT and MR Image Registration: Closing the Loop for Bone Sarcoma Treatment Planning.
Journal of imaging informatics in medicineMechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.
BiomoleculesPrognostic factors and management of elderly sarcoma in Japan: the population-based National Cancer Registry (NCR) in Japan.
International journal of clinical oncologyCorrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606].
Annals of oncology : official journal of the European Society for Medical OncologyThe role of positron emission tomography in the evaluation and management of musculoskeletal lesions-a narrative review.
Annals of jointIs Proximal Femur Reconstruction With a Vascularized Fibula and Allograft Successful at Reconstructing a Tumor Resection in Children 6 Years of Age or Younger?
Clinical orthopaedics and related researchAdjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028.
ESMO openRadiotherapy combined with locoregional hyperthermia for oligoprogression in metastatic melanoma local control.
Therapeutic advances in medical oncologySystemic inflammation index is a predictive and prognostic factor in patients with liposarcoma or leiomyosarcoma treated with trabectedin.
Scientific reportsEvaluating the transfer of surgical skills from simulation on synthetic bone to cadaveric bone osteosynthesis.
Orthopaedics & traumatology, surgery & research : OTSRTrends of publications on primary sarcomas of bone: A bibliometric analysis.
Journal of clinical orthopaedics and traumaRadiotherapy for osteoblastoma: the 25-year institutional experience.
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyTwo-stage revision for infection of oncological megaprostheses : a multicentre EMSOS study.
The bone & joint journalHealth networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).
ESMO openNon-Operative Ttreatment of patients with Chondrosarcoma: An analysis of patients who refused cancer-directed surgery or patients contraindicated to surgery.
Acta orthopaedica BelgicaElective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyBone sarcomas and cancer predisposition syndromes.
Bulletin du cancerIncidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results.
European journal of cancer (Oxford, England : 1990)Long-term outcome after a limb salvage procedure using a femoral head allograft following the resection of a synovial sarcoma affecting the hindfoot.
BMJ case reportsRecommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy.
Neurologia i neurochirurgia polskaPediatric Bone Sarcoma Biopsy Tract Excision: Is it Safe to Resect Separately?
Journal of pediatric orthopedicsPrecision medicine in diagnosis, prognosis, and disease monitoring of bone and soft tissue sarcomas using liquid biopsy: a systematic review.
Archives of orthopaedic and trauma surgerySimilar risks of complications and reoperation rates in proximal femur megaprostheses for oncological and non-oncological indications.
International orthopaedicsImplant failure of the Compress prosthesis: a case report.
Journal of medical case reportsThe effect of intraoperative radiotherapy in musculoskeletal malignancy: A population study from US SEER database.
Journal of CancerOutcomes of Scapular Osteosarcoma.
Anticancer researchLymphadenectomy in the treatment of sarcomas - indications and technique.
Oncology reviewsTranscriptional regulation of KCNA2 coding Kv1.2 by EWS::FLI1: involvement in controlling the YAP/Hippo signalling pathway and cell proliferation.
Cell communication and signaling : CCSUnusual "Mini-Rugby Ball" Pattern Solitary Lung Metastasis in Relapsed Ewing's Sarcoma.
World journal of nuclear medicineA comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.
European journal of cancer (Oxford, England : 1990)Breaking barriers: The impact of telemedicine on improving soft tissue and bone tumor management in Armenia.
Journal of cancer policyOutcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.
European journal of cancer (Oxford, England : 1990)Orthopedic Surgeons at Greater Risk of Malpractice Claims for Treatment of Primary Malignant Bone and Soft Tissue Tumors Compared With Metastatic Bone Disease.
Journal of surgical oncologyCommon on: "Obesity Increases the Risk of Major Wound Complications Following Pelvic Resection for Bone Sarcoma".
Journal of surgical oncologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Sarcoma ósseo.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Sarcoma ósseo
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy.
- Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.
- Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
- Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.
- Recycled tumor bone and/or vascularised fibula graft reconstruction for intercalary resections for sarcoma of femur.Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association· 2026· PMID 41577520mais citado
- Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?
- Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease.
- Physical activity after local therapy for pediatric bone sarcoma: an accelerometry-based analysis.
- What shapes satisfaction with daily life participation? Insights into functional outcomes after pediatric bone sarcoma treatment.
- The Role of Race and Ethnicity on Time to Treatment in Orthopaedic Oncology.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:223727(Orphanet)
- MONDO:0021054(MONDO)
- GARD:20547(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q56014469(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
